by Andrii Buvailo, PhD
Generating drug candidate ideas has become inexpensive, and the supply of hypotheses now exceeds any organization’s capacity to evaluate them. Schrödinger’s answer, launched at the end of July, is Bunsen: …
Read More
by Andrii Buvailo, PhD
Techbio company WhiteLab Genomics has raised a $26 million Series B to develop and license its own AI-designed gene delivery technologies, moving beyond the computational services business it started with. …
Read More
by Andrii Buvailo, PhD, Roman Kasianov
Inside the growing bet that AI can find the patients pharma's failed trials missed... Update (October 2026): Five months after this piece was first published, Biossil raised another $153 million …
Read More
by Andrii Buvailo, PhD
Isomorphic Labs has raised about $2.7 billion from outside investors since 2025. Its president, Max Jaderberg, says its drug design engine works, but the company has not publicly named a …
Read More
by Anastasiia Rohozianska, Roman Kasianov
Recently, Iambic Therapeutics has filed to go public on Nasdaq under the ticker IAM, adding another closely watched name to a biotech IPO market that has begun to reopen after …
Read More
by Andrii Buvailo, PhD
Three AI drug discovery companies raised a combined $526 million on September 23 and 24. One mines plants and microbes for new medicines. One trains its models on what it …
Read More
